- Home
- FCNCP vs MIRM Comparison
FCNCP vs MIRM Comparison
Compare FCNCP & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCNCP
- MIRM
- Stock Information
- Founded
- FCNCP N/A
- MIRM 2018
- Country
- FCNCP United States
- MIRM United States
- Employees
- FCNCP 16021
- MIRM N/A
- Industry
- FCNCP Major Banks
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- FCNCP Finance
- MIRM Health Care
- Exchange
- FCNCP Nasdaq
- MIRM Nasdaq
- Market Cap
- FCNCP N/A
- MIRM 1.9B
- IPO Year
- FCNCP N/A
- MIRM 2019
- Fundamental
- Price
- FCNCP $20.78
- MIRM $40.80
- Analyst Decision
- FCNCP
- MIRM Strong Buy
- Analyst Count
- FCNCP 0
- MIRM 11
- Target Price
- FCNCP N/A
- MIRM $58.55
- AVG Volume (30 Days)
- FCNCP N/A
- MIRM 438.4K
- Earning Date
- FCNCP N/A
- MIRM 05-07-2025
- Dividend Yield
- FCNCP N/A
- MIRM N/A
- EPS Growth
- FCNCP N/A
- MIRM N/A
- EPS
- FCNCP N/A
- MIRM N/A
- Revenue
- FCNCP N/A
- MIRM $336,888,000.00
- Revenue This Year
- FCNCP N/A
- MIRM $29.51
- Revenue Next Year
- FCNCP N/A
- MIRM $20.27
- P/E Ratio
- FCNCP N/A
- MIRM N/A
- Revenue Growth
- FCNCP N/A
- MIRM 80.76
- 52 Week Low
- FCNCP N/A
- MIRM $23.83
- 52 Week High
- FCNCP N/A
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- FCNCP 49.09
- MIRM 45.27
- Support Level
- FCNCP $19.54
- MIRM $38.22
- Resistance Level
- FCNCP $20.78
- MIRM $39.87
- Average True Range (ATR)
- FCNCP 0.37
- MIRM 2.27
- MACD
- FCNCP 0.15
- MIRM 0.23
- Stochastic Oscillator
- FCNCP 93.80
- MIRM 61.83
About FCNCP First Citizens BancShares Inc.
First Citizens BancShares Inc is the bank holding company of First Citizens Bank & Trust Company. FCB was founded as the Bank of Smithfield in North Carolina and has expanded through both de novo branching and acquisitions. FCB currently operates in nearly half of the continental United States, but principally takes deposits in the Carolinas. The bank's operations have historically been influenced by the Holding family, which has traditionally held executive and director positions, as well as controlling a large percentage of its outstanding stock. FCB provides a wide range of retail and commercial banking services, including traditional lending and deposit-taking, as well as trust and wealth management. FCB's main source of revenue is net interest income.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.